Skip to main
NHI

NHI Stock Forecast & Price Target

NHI Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

National Health Investors is expected to experience growth in the coming years, with its deep investment pipeline, low-levered balance sheet, and below-average cost of capital as main factors contributing to this growth. Despite recent events such as the non-cash write-off of straight-line rent and the sale of its NHC portfolio, the company remains undervalued and presents an attractive entry point into a multi-year growth story. However, there are potential risks such as underperformance if rent resets are lower than anticipated or if there is weaker deferred rent collection, and investors may need to show patience for the company to rebuild its NOI to pre-deal levels after the sale of the NHC portfolio. In the long run, the company's decision to prioritize improved growth over short-term market gains is the right strategic move for its future success.

Bears say

National Health Investors is facing a negative outlook due to lowered FFO estimates for 2026 and 2027, which reflect a decline in normalized FFOps in 2026 followed by a modest growth in 2027. This is primarily due to the dilution caused by the portfolio sale with proceeds being used to repay debt rather than being reinvested. Moreover, the company's high dependence on its top few operators and recent disappointing results for its existing SHOP portfolio also contribute to the negative outlook. However, the company has potential for growth through new investments and organic growth in the senior housing and healthcare sector.

NHI has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of National Health Investors and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About National Health Investors (NHI) Forecast

Analysts have given NHI a Buy based on their latest research and market trends.

According to 6 analysts, NHI has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

National Health Investors (NHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.